Inactive Instrument

Xynomic Pharmaceuticals Holdings, Inc.

XYN

US98421X1028

Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019

June 01, 2020 at 06:57 am

Xynomic Pharmaceuticals Holdings, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced operating loss was USD 25.038 million compared to USD 28.571 million a year ago. Net loss was USD 25.103 million compared to USD 28.587 million a year ago. Basic loss per share from continuing operations was USD 0.83 compared to USD 3.85 a year ago.

Latest news about Xynomic Pharmaceuticals Holdings, Inc.

Xu-Nuo Pharma, Inc. acquired the remaining 2% stake in Xynomic Pharmaceuticals Holdings, Inc..	21-06-16	CI
Xynomic Pharmaceuticals Holdings, Inc. Announces Resignation of Richard Peidong Wu as Independent Director and the Chairman of the Audit Committee	20-06-29	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-06-01	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-14	CI
Xynomic Pharmaceuticals Holdings, Inc. Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma	19-09-23	CI
Xynomic Pharmaceuticals Holdings, Inc. Announces Management Changes	19-09-20	CI
Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial	19-09-13	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda in Multiple Solid Tumors	19-08-30	CI
Xynomic Research Institute Has Successfully Designed a Series of Potent RET Kinase Inhibitors	19-08-16	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-15	CI
Xynomic Pharmaceuticals Holdings, Inc. Approves Application to Conduct Pivotal Phase 3 Trial Using Abexinostat	19-08-07	CI
Xynomic Pharmaceuticals Holdings, Inc. Files Fast-Track Designation Application for Follicular Lymphoma Treatment with the U.S. FDA	19-08-01	CI
Xynomic Pharmaceuticals Holdings, Inc. Receives China Approval to Start 2 Pivotal Lymphoma Clinical Trials	19-07-30	CI
Xynomic Pharmaceuticals Holdings, Inc. announced that it expects to receive $14.999998 million in funding	19-07-09	CI
Xynomic Pharmaceuticals Holdings, Inc. Announces Board Changes	19-07-05	CI
Xynomic Pharmaceuticals Holdings, Inc. Completes Pre-IND Meeting with US FDA for XP-102	19-06-12	CI
Xynomic Pharmaceuticals Holdings, Inc. Doses First Patient in Phase 1/2 Lymphoma Trial	19-06-06	CI
Xynomic Pharmaceuticals Holdings, Inc.(NasdaqCM:XYN) added to NASDAQ Composite Index	19-05-15	CI
Xynomic Pharmaceuticals, Inc completed the acquisition of Bison Capital Acquisition Corp. in a reverse merger transaction.	19-05-14	CI
Xynomic Pharmaceuticals, Inc Appoints Jinwei Coco Kou as the Interim Chief Accounting Officer	19-03-20	CI
China, Spain and Poland Authorities Approves Xynomic Pharmaceuticals, Inc.'s Application	19-03-16	CI
Xynomic Pharma Appoints Dr. Sophia Paspal as the Vice President, Regulatory Affairs and Quality Assurance	19-02-27	CI
Xynomic Pharma Will Present at ASCO-GU Cancers Symposium, Files 3 INDs for Potentially Pivotal Cancer Trials in China, and Expands R&D Operations	18-12-27	CI
Xynomic Pharmaceuticals, Inc entered into a non-binding letter of intent to acquire Bison Capital Acquisition Corp. in a reverse merger transaction.	18-09-11	CI
Xynomic Pharmaceuticals, Inc. announced that it has received funding from Northern Light Venture Capital, Hakim Unique Internet Co., Ltd., Shanghai Prosperico Ventures Co., Ltd., and other investors	18-05-31	CI

Chart Xynomic Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Xynomic Pharmaceuticals Holdings, Inc.

More charts

Company Profile

XYNOMIC PHARMACEUTICALS HOLDINGS, INC. is a China-based biopharmaceutical company. The Company, together with its subsidiaries, are principally engaged in in-licensing, developing and commercializing oncology drug candidates in the People's Republic of China (PRC), the United States, and rest of the world. To date, the Company has not yet generated any revenue from product sales.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-2.61%	89.08B
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.9B
BIOGEN INC.	-14.40%	32.25B
UCB	+55.89%	25.14B
BIOMARIN PHARMACEUTICAL INC.	-15.96%	15.39B
INCYTE CORPORATION	-15.50%	11.91B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	11.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.87%	9.03B

Biopharmaceuticals